🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06280508
Recruiting Phase 2

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

NCT06280508 · tracked via the Priya Life Science China tracker
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase
Phase 2
Started
2024-03-01
Last updated
2024-04-23

Condition(s) studied

Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

Investigational drug(s) / intervention(s)

Adebrelimab, Apatinib, Gemcitabine, cisplatin

Adebrelimab, Apatinib, Gemcitabine, cisplatin: Chemotherapy combined with Adebrelimab and Apatinib neoadjuvant therapy for 3 cycles before surgery, and Adebrelimab combined with Apatinib adjuvant therapy for 6 months after surgery

Study summary

This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * confirmed intrahepatic cholangiocarcinoma * with Resectable tumor lesion * no contraindications to surgery * with high risk of tumour recurrence * No prior systemic therapy for intrahepatic cholangiocarcinoma. * ECOG Performance Status of 0 or 1 * Child-Pugh Class: Grade A Exclusion Criteria: * History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage * Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment * Known genetic or acquired hemorrhage or thrombotic tendency * Thrombosis or thromboembolic event within 6 months prior to the start of study treatment * Cardiac clinical symptom or disease that is not well controlled * Hypertension that can not be well controlled through antihypertensive drugs

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Guangzhou China/Guangdong Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06280508 on ClinicalTrials.gov ↗ ← All trials in China